Acting FDA Commissioner Kyle Diamantas says he will not seek permanent appointment

Acting FDA Commissioner Kyle Diamantas has indicated that he does not intend to remain in the role on a permanent basis. Sources close to the administration say that the search for a new permanent commissioner is already under way.

The decision comes as the agency continues to manage ongoing regulatory initiatives and product reviews. Industry observers note that leadership stability at the FDA can influence drug approval timelines and policy direction.

Stakeholders will be watching for the next nominee, whose appointment could shape the agency’s approach to emerging therapies and public health priorities.